LGND Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
63.7M
+23.1%
51.7M
-13.3%
59.7M
-48.3%
115.5M
+142.4%
47.6M
Cost of Revenue
11.3M
-0.5%
11.4M
+280.0%
3.0M
-21.3%
3.8M
-66.0%
11.2M
Gross Profit
52.4M
+29.8%
40.4M
-28.8%
56.7M
-49.2%
111.7M
+206.2%
36.5M
Operating Expenses
43.8M
+90.5%
23.0M
-46.3%
42.8M
-25.6%
57.6M
+115.2%
26.7M
R&D
14.7M
+582.9%
2.1M
-38.8%
3.5M
-83.3%
21.0M
+220.1%
6.6M
SG&A
29.1M
+39.8%
20.8M
-16.7%
25.0M
-12.0%
28.4M
+41.0%
20.2M
Operating Income
8.6M
-50.5%
17.4M
+25.5%
13.8M
-74.4%
54.1M
+456.6%
9.7M
EBITDA
16.8M
-34.3%
25.6M
-9.4%
28.3M
-54.7%
62.4M
+241.9%
18.2M
Net Income
48.5M
+463.5%
-13345000
-129.8%
44.8M
-61.8%
117.3M
+2319.5%
4.8M
EPS (Basic)
$2.42
+461.2%
$-0.67
-128.8%
$2.33
-61.1%
$5.99
+2296.0%
$0.25
EPS (Diluted)
$2.22
+431.3%
$-0.67
-132.1%
$2.09
-63.2%
$5.68
+2266.7%
$0.24
Shares (Diluted)
21.8M
+9.8%
19.9M
-7.2%
21.4M
+3.9%
20.6M
+3.5%
19.9M
Ligand Pharmaceuticals (LGND) โ€” Financials